Global Cardiopulmonary Stress Testing Systems Mark
Global Cardiopulmonary Stress Testing Systems Market Size Expands to Touch USD 8.9 Billion by 2029
Published | 27 January 2023
Global cardiopulmonary stress testing systems market is flourishing because of an increasing focus on diagnosing rapidly growing prevalence of cardiovascular diseases and geriatric population.
BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global cardiopulmonary stress testing systems market size at USD 6.1 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global cardiopulmonary stress testing systems market size to grow at a significant CAGR of 5.6% reaching a value of USD 8.9 billion by 2029. Major growth factors of global cardiopulmonary stress testing systems market include growing elder population and rising prevalence of coronary artery disorders such as acute myocardial infarction and angina pectoris. Moreover, rising rates of lifestyle diseases, as well as heart and lung ailments, are driving the cardiopulmonary stress testing market. The cardiopulmonary test assesses and diagnoses heart failure, ischemic heart disease, shortness of breath, and pulmonary problems. As of 2013, cardiovascular diseases were the leading cause of mortality worldwide, which has been a major concern for WHO and numerous healthcare organizations throughout the world and is also projected to drive the cardiopulmonary stress testing devices market during the forecast period. Apart from that, increasing budgetary allocation and the provision of affordable care to patients are on the rise. This has prompted market participants to establish operations new markets and implement technologically advanced testing processes. Therefore, such factors are expected to boost the expansion of the overall market. However, stringent regulations and higher challenges during the development stage and expensive testing procedures are anticipated to restrain the market growth during the period in analysis.
Global Cardiopulmonary Stress Testing Systems Market – Overview
The cardiopulmonary stress test is an evaluation that allows the physician to examine the heart and lungs' function during exercise. The amount of oxygen a person consumes when riding a bike or walking on a treadmill is used to evaluate disorders such as dyspnea, hypertrophic cardiomyopathy, and pulmonary hypertension. The increased prevalence of cardiovascular illnesses and pulmonary ailments is a primary driver of market expansion. One of the primary causes leading to the expansion is an increase in the global prevalence of numerous cardiovascular indications, such as atrial fibrillation, which necessitates the testing of cardiopulmonary function. Furthermore, the increased prevalence of lifestyle diseases, as well as heart and lung disorders, is propelling the cardiopulmonary stress testing market. The cardiopulmonary test evaluates and detects cardiac failures, ischemic heart disease, shortness of breath, and pulmonary issues. The expanding geriatric population is one of the market's primary drivers. According to the United Nations, by 2050, elderly people will make up more than 25% of the population in Europe and North America; 20% in Oceania; 17% in Asia, Latin America, and the Caribbean; and 6% in Africa.
Sample Request @ https://www.blueweaveconsulting.com/report/cardiopulmonary-stress-testing-systems-market/report-sample
Impact of COVID-19 on Global Cardiopulmonary Stress Testing Systems Market
COVID-19 had a minor impact on the market for cardiopulmonary stress testing systems. It is the most common type of cardiac surgery performed worldwide, and it is a life-saving technique for individuals with serious heart illness and pulmonary disease. Hospitalizations for arrhythmia, heart failure, ischemic heart disease, dyspnea, and heart valve imbalance decreased dramatically as a result of the pandemic. Furthermore, the pandemic is disrupting the medical supply chain, and many enterprises will shift to other geographic zones in the future to assure product availability and supply chain protection. As a result, the COVID-19 pandemic has had an impact on the market. However, the situation is predicted to steadily improve over the forecast period.
Global Cardiopulmonary Stress Testing Systems Market – By Product Type
By product type, global cardiopulmonary stress testing systems market is segmented into Stress Blood Pressure Monitors, Exercise Testing Systems, and Stress ECG. The exercise testing systems segment is expected to hold the highest market share due to its precision and short running duration. Furthermore, the rising choice for these systems by physicians and patients due to their cost-effectiveness and diverse applications contributes to the rise in adoption of these systems, propelling market expansion. However, the stress ECG device segment is establishing its dominance in the global cardiopulmonary stress testing systems market over the projected period due to an increasing senior population with diminishing functional capability. Schiller AG is the global market leader in cardiopulmonary stress testing services. The product pipeline and technology for patient assessment via stress testing at the company have been continuously developed. The CARDIOVIT AT-200 EXCELLENCE ERGOSPIRO is a device that can conveniently and reliably perform both pulmonary function tests (PFTs) and metabolic tests with diagnostic quality-12 or 16-lead exercise ECG.
Competitive Landscape
Major players operating in global cardiopulmonary stress testing systems market include Thermo Fisher Scientific Ltd., Philips Healthcare, Care Medical Ltd., Cosmed Medical and Cardiac Science Corporation, GE Healthcare, Cardinal Health, CareFusion Corporation (BD), Spacelabs Healthcare (OSI Systems, Inc.), MGC Diagnostic Corporation, Nihon Kohden Corporation, Schiller AG, SunTech Medical, Inc., Welch Allyn, Hill-Rom Holdings Inc, and OSI Systems Inc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.
The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Cardiopulmonary Stress Testing Systems Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Cardiopulmonary Stress Testing Systems Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.
About Us
BlueWeave Consulting provides comprehensive Market Intelligence (MI) Solutions to businesses regarding various products and services online and offline. We offer all-inclusive market research reports by analyzing qualitative and quantitative data to boost the performance of your business solutions. BlueWeave has built its reputation by delivering quality inputs and nourishing long-lasting relationships with its clients. We are one of the promising digital MI solutions companies providing agile assistance to make your business endeavors successful.
Contact Us:
BlueWeave Consulting & Research Pvt. Ltd
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662
Get Help
Related Report
Publish Date: January 2023
Growing geriatric population and rising prevalence of cardiovascular diseases are projected to propel the expansion of global cardiopulmonary stress testing systems market during the forecast period between 2023 and 2029.
Relevant Press Releases
- IgA Nephropathy Disease Treatment Market to Surpass USD 485 Million by 2028
- Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Size Set to Touch USD 5.5 Billion by 2029
- UAE Pharmaceutical Gelatin Market Size Set to Touch Whopping USD 22.47 Million by 2029
- Global Central Fill Pharmacy Automation Market to Reach USD 887 Million by 2028
- Asia Pacific Hemodialysis and Peritoneal Dialysis Market Size Set to Expand at Significant CAGR Touching USD 20 Billion by 2030